We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Derived Exosomal Protein Biomarkers in Alzheimer’s Disease Diagnosis

By LabMedica International staff writers
Posted on 04 Aug 2016
Alzheimer’s disease results in brain neuronal plaques composed of amyloid beta peptide (Aβ42) and neurofibrillary tangles composed of phosphorylated tau proteins (P-T181-tau and P-S396-tau). More...
Exosomes are shed by brain neurons, freely cross the blood brain barrier and protect and carry proteins from their cellular origin into plasma.

P-T181-tau and P-S396-tau are present at higher than normal concentrations and Aβ42 at lower than normal concentrations in the cerebrospinal fluid of Alzheimer’s disease (AD) patients. These proteins are not high in plasma samples of AD patients in part due to poor blood brain barrier transport and protease activities.

Scientists at Pan Laboratories (Irvine, CA, USA) and their colleagues validated enzyme-linked immunosorbent assays (ELISA) for Aβ42, P-T181-tau and P-S396-tau, and used them to quantify these proteins in neuron-derived exosomal extracts from normal and AD plasma samples. Plasma samples were obtained from patients with mild cognitive impairment (MCI) and dementia due to Alzheimer’s disease (AD), as well as matched normal controls. Exosomes were precipitated from the plasma samples using the ExoQuick preparation (System Biosciences, Palo Alto, CA, USA).

The team reported that ELISA assays for Aβ42, P-T181-tau and P-S396-tau were reproducible and the Inter-assay Coefficient of Variability (CV) was less than 15%. The sensitivity of the biomarker ELISAs varied from 2 to10 pg/mL. Neuron-specific exosomes were prepared from the plasma of normal controls, MCI and AD patients. The reproducibility of the exosome preparations and biomarker levels were monitored in each ELISA. All biomarkers were elevated in MCI patients and AD patients compared to normal.

The authors concluded that they have validated a reproducible procedure to isolate specific neuron-derived exosomes for quantification of specific protein biomarkers in plasma samples. The concentrations of the biomarkers are high in patients with early dementia and Alzheimer’s disease. This procedure may be useful in the early diagnosis of Alzheimer’s disease. The study was presented at the 68th American Association of Clinical Chemistry (AACC) Annual Scientific Meeting held July 31 to August 4, 2016, in Philadelphia, PA, USA.

Related Links:
Pan Laboratories
System Biosciences
American Association of Clinical Chemistry

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Platelet Function Analyzer
PL-12
Automated Clinical Chemistry Analyzer
Envoy 500+
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.